At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 423 enrolled
Drug / intervention
MEDI6570 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIB, Randomized, Double Blinded, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of MEDI6570 in Participants With a Prior Myocardial Infarction and Persistent Inflammation
In Brief
A Phase 2 clinical trial evaluating MEDI6570 and Placebo for Coronary Heart Disease (CHD). Completed, enrolled 423 participants across 84 sites in 11 countries.
Detailed Summary
A Phase IIB Parallel group Study to Evaluate the Efficacy and Safety of MEDI6570 in Participants with a Prior Myocardial Infarction.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Heart Disease (CHD)
CountriesAustralia, Canada, Czechia, Hungary, Italy, Japan, Netherlands, Poland, Spain, United Kingdom, United States
CollaboratorsThe TIMI Study Group
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedNov 2020
Enrollment StartNov 2020
Primary CompletionNov 2023
TodayJul 2026
First PostedNov 2, 2020
Enrollment StartNov 4, 2020
Primary CompletionNov 8, 2023
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 5.7 years ago
Interventions
MEDI6570biological
MEDI6570
Placebobiological
Buffer